



Keep pace with rapid advances in cancer treatment.

Stay informed about the latest evidence-based updates on cancer therapies, safety, and side effect management – empowering interprofessional teams to deliver exceptional care.

LIVE WEBINAR



Thursday, September 3, 2026

1:00 – 2:00 PM EDT

REGISTER

<https://education.nccn.org/node/98662>

AVAILABLE CREDIT

- 1.0 AAPA Category 1 CME credit
- 1.0 ACPE contact hour
- 1.0 AMA PRA Category 1 Credit™
- 1.0 ANCC contact hour
- 1.0 ANCC pharmacology contact hour
- 1.0 Participation

OVERVIEW

The treatment landscape for SCLC has historically been stagnant; however, immunotherapy has been making inroads into treatment options in the frontline and relapsed/refractory setting. Analyzing overall survival in conjunction with expected toxicities will help guide clinicians to select the most appropriate treatment. Supportive care draws on interprofessional teams to address smoking cessation, SIADH, Cushing syndrome, and Lamber-Eaton myasthenic syndrome.

Small Cell Lung Cancer: Is Immunotherapy Moving the Needle?



PRESENTED BY:

Melvin Rivera, PharmD, BCOP
*The University of Texas
MD Anderson Cancer Center*

LEARNING OBJECTIVES:

- Examine the progression of systemic therapy options in SCLC with a focus on the impact of immunotherapy.
- Review clinical studies for immunotherapy and interpret how they impact patient survival outcomes.
- Summarize supportive care treatment recommendations for SCLC.

TARGET AUDIENCE:

This program is designed to meet the educational needs of physicians, nurses, nurse practitioners, pharmacists, physician associates and other health care professionals who treat patients with cancer.